Celebrating its 10th anniversary, the Microbiome Movement USA Summit will reunite the community with perspectives from 140+ ...

The Dermatology Drug Development Summit Europe returns for its 6th year as the premier industry forum dedicated to advancing ...

Lilly and Novartis have collectively pledged almost $3 billion to their partnerships with Isomorphic signed last year, which ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Dr Marks formally resigned from his post on 28th March and is due to step down on 5th April, and his resignation letter ...

But, of course, young people themselves need to be offered a place at the table to make the changes they need for their own ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident. Ben Hargreaves examines how the drugs have been a major ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler, more ...

As the news that NHS England is to be dismantled sinks in, the British Medical Association (BMA) and other bodies have weighed in on the decision. According to Prof Phil Banfield, chair of the BMA ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...